Diclofenac re-scheduling declined

A bid to allow higher strength topical diclofenac to be made available for general sale has been rejected by the TGA.

The agency’s Advisory Committee on Medicines Scheduling rejected an application to amend the current Schedule 2 diclofenac entry to allow 2% dermal preparations to be available for retail sale.

A submission opposing the move said that increasing the strength of topical NSAID to double what is currently exempt from scheduling would pose a risk to public health.